Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Oruka Therapeutics, Inc. (ORKA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$101.41+1.87%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ORKA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advancement of ORKA-001 in clinical trials | Oruka Therapeutics is advancing its lead product, ORKA-001, in clinical trials. | Intact | Phase 2 trials fail to meet endpoints | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ORKA is an early-stage clinical development company, so its investment case depends on advancing drug candidates rather than reported revenue growth. The long-term thesis is in a watch state: ORKA-001 has shown clinical progress, but execution and financial performance remain weak.
The evidence does not provide a valuation measure or a clear account of market expectations, so whether ORKA is cheap or expensive versus peers cannot be assessed. The priced-in evidence points to low fragility, with sector turbulence rather than a broader combination of expensive valuation, weak fundamentals, and turbulence.
Near term, recent financial performance is weak and the company recorded an earnings miss; its latest reported cash balance was $1.1 billion, which management said should fund operations through an anticipated ORKA-001 BLA filing and continued ORKA-002 development. Over the multi-year view, ORKA-001’s Week 16 results support planned Phase 3 trials in the first half of 2027, while ORKA-002 has begun a Phase 2 trial and has a data milestone expected in the first quarter of 2027. The recent litigation filing adds uncertainty, and the evidence does not describe its details.
The thesis hinges on ORKA-001 advancing toward Phase 3 and ORKA-002 delivering its pending clinical milestones, while cash supports development through the planned filing. Near term, weakening jobs data could weigh on cyclical names, while continued strength or weakness among healthcare bellwethers could either sustain or fade the sector tailwind.
Over the next one to three years, ORKA’s case rests on clinical execution and adequate cash runway, but weak recent performance, elevated risk, and unresolved milestones keep the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| This financial strength is crucial for reaching regulatory milestones. |
| Intact |
| Cash falls below $900 million |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Monitor insider trading activity | A supporting condition in Oruka Therapeutics, Inc.'s published investment case. The stated target is No significant insider selling. | Under Pressure | Significant insider selling occurs | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.51 → $-2.83 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.51 | Unavailable | 7 / 0 |
| 2026-07-25 | $-2.51 | Unavailable | 7 / 0 |
| 2026-07-26 | $-2.51 | Unavailable | 7 / 0 |
| 2026-07-27 | $-2.49 | $0 | 9 / 9 |
| 2026-07-28 | $-2.51 | Unavailable | 7 / 0 |
| 2026-07-29 | $-2.49 | $0 | 9 / 9 |
| 2026-07-30 | $-2.49 | $0 | 9 / 9 |
| 2026-07-31 | $-2.49 | $0 | 9 / 9 |
| 2026-08-01 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-02 | $-2.49 | $0 | 9 / 9 |
| 2026-08-03 | $-2.49 | $0 | 9 / 9 |
| 2026-08-04 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-05 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-06 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-07 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-08 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-09 | $-2.49 | $0 | 9 / 9 |
| 2026-08-10 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-12 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-13 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-14 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-15 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-16 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-17 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-18 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-19 | $-2.51 | Unavailable | 7 / 0 |
| 2026-08-20 | $-2.70 | Unavailable | 7 / 0 |
| 2026-08-21 | $-2.70 | Unavailable | 7 / 0 |
| 2026-08-22 | $-2.70 | Unavailable | 7 / 0 |
| 2026-08-23 | $-2.68 | Unavailable | 7 / 0 |
| 2026-08-24 | $-2.68 | Unavailable | 7 / 0 |
| 2026-08-25 | $-2.73 | Unavailable | 7 / 0 |
| 2026-08-26 | $-2.73 | Unavailable | 7 / 0 |
| 2026-08-27 | $-2.73 | Unavailable | 7 / 0 |
| 2026-08-28 | $-2.73 | Unavailable | 7 / 0 |
| 2026-08-29 | $-2.79 | Unavailable | 7 / 0 |
| 2026-08-30 | $-2.79 | Unavailable | 7 / 0 |
| 2026-08-31 | $-2.79 | Unavailable | 7 / 0 |
| 2026-09-01 | $-2.79 | Unavailable | 7 / 0 |
| 2026-09-02 | $-2.79 | Unavailable | 7 / 0 |
| 2026-09-03 | $-2.79 | Unavailable | 7 / 0 |
| 2026-09-04 | $-2.79 | Unavailable | 7 / 0 |
| 2026-09-05 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-06 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-07 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-08 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-09 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-10 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-11 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-12 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-13 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-14 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-15 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-16 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-17 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-18 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-19 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-20 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-21 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-22 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-23 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-24 | $-2.81 | Unavailable | 7 / 0 |
| 2026-09-25 | $-2.83 | Unavailable | 7 / 0 |
| 2026-09-26 | $-2.83 | Unavailable | 7 / 0 |
| 2026-09-27 | $-2.83 | Unavailable | 7 / 0 |
| 2026-09-28 | $-2.83 | Unavailable | 7 / 0 |
| 2026-09-29 | $-2.83 | Unavailable | 7 / 0 |
| 2026-09-30 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-01 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-02 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-03 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-04 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-05 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-06 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-07 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-08 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-09 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-10 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-11 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-12 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-13 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-14 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-15 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-16 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-17 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-18 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-19 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-20 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-21 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-22 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-23 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-24 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-25 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-26 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-27 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-28 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-29 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-30 | $-2.83 | Unavailable | 7 / 0 |
| 2026-10-31 | $-2.83 | Unavailable | 7 / 0 |
| 2026-11-01 | $-2.83 | Unavailable | 7 / 0 |
| 2026-11-02 | $-2.83 | Unavailable | 7 / 0 |
| 2026-11-03 | $-2.83 | Unavailable | 7 / 0 |
| 2026-11-04 | $-2.83 | Unavailable | 7 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.